Samsung Biologics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	5,121,219	4,556,972	3,497,146	3,694,589	3,001,295	1,568,007
Other Revenue	-0	-0	-0	-	-0	-
Revenue	5,121,219	4,556,972	3,497,146	3,694,589	3,001,295	1,568,007
Revenue Growth	50.31%	30.30%	-5.34%	23.10%	91.41%	34.62%
Cost of Revenue	2,345,039	2,056,131	1,798,093	1,900,080	1,540,526	844,657
Gross Profit	2,776,180	2,500,841	1,699,053	1,794,509	1,460,769	723,350
Selling, General & Admin	369,572	357,259	313,046	535,421	380,456	169,630
Research & Development	37,235	37,181	36,711	81,588	45,884	954.22
Amortization of Goodwill & Intangibles	14,315	13,797	10,948	9,977	7,700	4,572
Other Operating Expenses	6,057	5,970	4,688	10,339	7,448	1,804
Operating Expenses	447,204	431,620	377,686	680,829	477,142	186,040
Operating Income	2,328,976	2,069,221	1,321,366	1,113,680	983,627	537,309
Interest Expense	-32,543	-29,171	-34,123	-81,596	-64,064	-14,707
Interest & Investment Income	51,332	46,034	54,404	95,650	53,293	9,656
Earnings From Equity Investments	1,203	43,085	2,659	-499.42	27,260	13,853
Currency Exchange Gain (Loss)	106,054	-7,447	41,832	-11,186	-63,503	17,874
Other Non Operating Income (Expenses)	13,160	2,352	1,361	2,652	2,347	4,494
EBT Excluding Unusual Items	2,468,181	2,124,074	1,387,500	1,118,701	938,960	568,479
Gain (Loss) on Sale of Investments	-	-	-	5,152	72,653	269.12
Gain (Loss) on Sale of Assets	-5,795	-5,443	-1,949	-3,866	-2,588	-7,466
Asset Writedown	-	-	-682.1	-	-	-
Pretax Income	2,462,387	2,118,631	1,384,869	1,119,987	1,009,025	561,283
Income Tax Expense	613,059	504,301	344,567	262,296	210,968	167,693
Earnings From Continuing Operations	1,849,328	1,614,330	1,040,302	857,691	798,056	393,589
Earnings From Discontinued Operations	134,984	170,022	43,014	-	-	-
Net Income to Company	1,984,312	1,784,352	1,083,316	857,691	798,056	393,589
Net Income	1,984,312	1,784,352	1,083,316	857,691	798,056	393,589
Net Income to Common	1,984,312	1,784,352	1,083,316	857,691	798,056	393,589
Net Income Growth	54.31%	64.71%	26.31%	7.47%	102.76%	63.33%
Shares Outstanding (Basic)	44	44	46	46	45	43
Shares Outstanding (Diluted)	44	44	46	46	45	43
Shares Change	-5.91%	-5.85%	-	1.95%	5.51%	-
EPS (Basic)	45556.40	40941.49	23402.33	18528.27	17592.79	9146.19
EPS (Diluted)	45556.40	40941.49	23402.33	18528.27	17577.11	9146.19
EPS Growth	64.00%	74.95%	26.31%	5.41%	92.18%	63.33%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	1,628,355	856,067	355,682	671,158	-3,792	48,343
Free Cash Flow Per Share	37384.24	19642.22	7683.62	14498.68	-83.52	1123.38
Gross Margin	54.21%	54.88%	48.58%	48.57%	48.67%	46.13%
Operating Margin	45.48%	45.41%	37.78%	30.14%	32.77%	34.27%
Profit Margin	38.75%	39.16%	30.98%	23.21%	26.59%	25.10%
Free Cash Flow Margin	31.80%	18.79%	10.17%	18.17%	-0.13%	3.08%
EBITDA	2,827,652	2,702,858	1,920,468	1,603,462	1,291,892	699,098
EBITDA Margin	55.21%	59.31%	54.92%	43.40%	43.04%	44.59%
D&A For EBITDA	498,676	633,637	599,101	489,782	308,264	161,789
EBIT	2,328,976	2,069,221	1,321,366	1,113,680	983,627	537,309
EBIT Margin	45.48%	45.41%	37.78%	30.14%	32.77%	34.27%
Effective Tax Rate	24.90%	23.80%	24.88%	23.42%	20.91%	29.88%
Advertising Expenses	-	6,615	7,180	11,916	8,829	5,349